Effect of polymerised type I collagen on hyperinflammation of adult outpatients with symptomatic COVID‐19
Journal
Clinical and Translational Medicine
ISSN
2001-1326
2001-1326
Date Issued
2022
Author(s)
Méndez‐Flores, Silvia
Priego‐Ranero, Ángel
Azamar‐Llamas, Daniel
Olvera‐Prado, Héctor
Rivas‐Redonda, Kenia Ilian
Ochoa‐Hein, Eric
Pérez-Ortiz, Andric C.
Rendón-Macías, Mario Enrique
Rojas-Castañeda, Estefano
Urbina-Terán, Said
Septién-Stute, Luis
Hernández-Gilsoul, Thierry
Aguilar-Morgan, Adrián Andrés
Fernández-Camargo, Dheni A.
Olivares-Martínez, Elizabeth
Hernández-Ramírez, Diego F.
Torres-Villalobos, Gonzalo
Type
text::journal::journal article
Abstract
Dear Editor: Although dexamethasone is approved for the hyperinflammation treatment of hospitalised COVID-19 patients, non-hospitalised patients do not benefit from this therapy.1 A potential drug for treating COVID-19 patients is polymerised type I collagen (PTIC). A downregulator of pro-inflammatory cytokines, adhesion molecules (ELAM-1, VCAM-1, and ICAM-1), cyclooxygenase (Cox)-1 enzyme and the collagenases expression through the modulation of transcription of factor NF-kB.2-6 The intramuscular or subcutaneous administration of PTIC to patients with active RA (Phase II studies) improved the count of swollen joints and morning stiffness; 57% of patients achieved an ACR score of 50, and 30% had disease remission with this therapeutic combination. PTIC was safe and well-tolerated in long-term treatment, without adverse effects. © Clinical and Translational Medicine